Expertise in
1
conditions

Dr. Nkechi I. Mba

Hematology | Oncology
Driscoll Children's Hospital
3533 S Alameda St, 
Corpus Christi, TX 
Accepting New Patients
Expertise in
1
conditions
Driscoll Children's Hospital
3533 S Alameda St, 
Corpus Christi, TX 

Overview

Nkechi Mba is a Hematologist and an Oncologist practicing medicine in Corpus Christi, Texas.

Dr. Mba is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Burkitt Lymphoma, Hereditary Spherocytosis, Rhabdoid Tumor, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 8 peer reviewed articles and participating in 45 clinical trials. Dr. Mba is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

Driscoll Children's Hospital
3533 S Alameda St, Corpus Christi, TX 78411

Additional Areas of Focus

Dr. Mba has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

45 Clinical Trials

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Other, Behavioral, Device
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2026
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Enrollment Status: Completed
Publish Date: July 31, 2026
Intervention Type: Drug, Behavioral, Other, Procedure
Study Drug: 6-Mercaptopurine
Study Phase: Phase 3
View 9 Less Clinical Trials

8 Total Publications

Adherence-enhancing intervention and relapse in childhood acute lymphoblastic leukemia: results from the Children's Oncology Group randomized trial ACCL1033.
Adherence-enhancing intervention and relapse in childhood acute lymphoblastic leukemia: results from the Children's Oncology Group randomized trial ACCL1033.
Journal: Leukemia
Published: November 06, 2025
Similar Doctors
Expertise in
48
conditions
Expertise in
48
conditions
Referral may be required

Corpus Christi Cancer Center PA

1625 Rodd Field Rd, 
Corpus Christi, TX 
 (4.8 miles away)
Languages Spoken:
English, French, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Aftab Mahmood is an Oncologist practicing medicine in Corpus Christi, Texas. Dr. Mahmood is highly rated in 48 conditions, according to our data. His clinical expertise encompasses Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Mahmood is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Christus Spohn Cancer Center-Shoreline

1415 Santa Fe St Fl 2 Ste C, 
Corpus Christi, TX 
 (1.5 miles away)
361-737-0600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sudhathi Chennuru is a Hematologist practicing medicine in Corpus Christi, Texas. Dr. Chennuru is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Thrombocytopenia, Monoclonal Gammopathy of Undetermined Significance (MGUS), Anemia, and Schnitzler Syndrome. Dr. Chennuru is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Christus Spohn Cancer Center-Shoreline

1415 Santa Fe St Fl 2 Ste C, 
Corpus Christi, TX 
 (1.5 miles away)
361-737-0600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Swetha Panati is a Hematologist practicing medicine in Corpus Christi, Texas. Dr. Panati is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Thrombocytopenia, Anemia, Squamous Cell Carcinoma of the Anal Canal (SCAC), and Gastroesophageal Junction Cancer. Dr. Panati is currently accepting new patients.

Frequently Asked Questions about Dr. Nkechi I. Mba

How do I make an appointment with Dr. Nkechi I. Mba?

You can book an appointment with Dr. Nkechi I. Mba by calling their office at 361-694-5311. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nkechi I. Mba a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nkechi I. Mba is classified as an Advanced expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nkechi I. Mba specialize in?

While Dr. Nkechi I. Mba is a Hematology, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Burkitt Lymphoma, and Hereditary Spherocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Nkechi I. Mba participate in research or clinical trials?

Yes. Dr. Nkechi I. Mba has published 8 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. Nkechi I. Mba's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Nkechi I. Mba accept my insurance?

Dr. Nkechi I. Mba accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 361-694-5311 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mba's expertise for a condition
ConditionClose
      View All 76 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile